Lykos Therapeutics

Lykos Therapeutics is a public benefit corporation developing investigational prescription psychedelics to transform mental healthcare, with an initial focus on post-traumatic stress disorder. The company applies decades of evidence-based research to catalyze therapeutic approaches for mental health conditions and is pursuing FDA approval for MDMA-assisted therapy so it can become more widely available to people with PTSD. Lykos previously received FDA authorization for an expanded access program covering up to 50 patients with PTSD; that program is fully enrolled and no longer accepting applications. As a public benefit corporation, Lykos says it focuses on positive impact for its people, communities, and society while destigmatizing conversations about mental health.